Daisuke Takayanagi
Overview
Explore the profile of Daisuke Takayanagi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishiguro T, Takeda K, Takayanagi D, Mura E, Suzuki R, Tsurui T, et al.
Cancer Genomics Proteomics
. 2024 Dec;
22(1):1-12.
PMID: 39730175
Background/aim: The Kaplan-Meier curves for patients treated with immune checkpoint inhibitors (ICIs) display a small group of potentially-cured patients with long-term survival, creating a 'kangaroo-tail' shape of the survival curve....
2.
Goshima T, Ieguchi K, Onishi N, Shimizu T, Takayanagi D, Watanabe M, et al.
Anticancer Res
. 2023 Dec;
44(1):23-29.
PMID: 38159965
Background/aim: The response rate to immune checkpoint inhibitors (ICIs) is approximately 10%-30% and only in a few cancer types. In the present study, we determined whether non-classical monocytes (NCMs) could...
3.
Shiraishi K, Takahashi A, Momozawa Y, Daigo Y, Kaneko S, Kawaguchi T, et al.
Cancer Commun (Lond)
. 2023 Oct;
44(2):287-293.
PMID: 37882647
No abstract available.
4.
Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, et al.
Front Immunol
. 2023 Oct;
14:1260492.
PMID: 37790929
Introduction: Programmed cell death ligand 1 (PD-L1) expression in tumor tissues is measured as a predictor of the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in many cancer types. PD-L1...
5.
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, et al.
Oncol Lett
. 2023 Aug;
26(3):381.
PMID: 37559573
Immune checkpoint inhibitors (ICIs) are among the most notable advances in cancer immunotherapy; however, reliable biomarkers for the efficacy of ICIs are yet to be reported. Programmed death (PD)-ligand 1...
6.
Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Machida E, et al.
Br J Cancer
. 2023 Aug;
129(7):1176-1183.
PMID: 37543670
Background: This study aimed to elucidate the clinicopathological and molecular features of HER2-amplified and HER2-low colorectal cancers (CRCs). We also characterised HER2 expression statuses in CRCs focusing on their intratumoral...
7.
Yamada K, Shiraishi K, Takashima A, Takayanagi D, Saiki Y, Takano S, et al.
Int J Clin Oncol
. 2023 Apr;
28(8):990-998.
PMID: 37115427
The definition of the anal canal was revised in the TNM classification (8th edition). The Japanese Society for Cancer of the Colon and Rectum (JSCCR) conducted a retrospective multi-institutional study...
8.
Shirasawa M, Yoshida T, Shiraishi K, Takigami A, Takayanagi D, Imabayashi T, et al.
Lung Cancer
. 2023 Apr;
179:107183.
PMID: 37037178
Background: Platinum etoposide plus anti-programmed cell death ligand-1 (PD-L1) antibody therapy is the standard of care for extensive-stage small cell lung cancer (ES-SCLC). However, patient characteristics associated with the efficacy...
9.
Ito T, Takayanagi D, Sekine S, Hashimoto T, Shimada Y, Matsuda M, et al.
Sci Rep
. 2023 Mar;
13(1):3587.
PMID: 36869079
Anal squamous cell carcinoma (ASCC) is a rare tumor of the gastrointestinal tract. We aimed to compare the genetic backgrounds and their effect on clinical outcomes between Japanese and Caucasian...
10.
Asami Y, Hiranuma K, Takayanagi D, Matsuda M, Shimada Y, Kato M, et al.
Sci Rep
. 2022 Nov;
12(1):19004.
PMID: 36347927
Lymph node metastasis (LNM) is a well-established prognostic factor in endometrial cancer (EC). We aimed to construct a model that predicts LNM and prognosis using preoperative factors such as myometrial...